Overview Bexarotene With Narrow-Band UVB for Psoriasis Status: Completed Trial end date: 2005-08-01 Target enrollment: Participant gender: Summary To determine if bexarotene gel with NBUVB phototherapy is more effective than placebo plus NBUVB for moderate to severe plaque-type psoriasis. Phase: Phase 2 Details Lead Sponsor: University of Medicine and Dentistry of New JerseyCollaborator: Ligand PharmaceuticalsTreatments: Bexarotene